Analyse Edwards Lifesciences Corporation (EW) — Kairos Score 59/100

À propos de Edwards Lifesciences Corporation

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Informations clés

🕴️ Activité des initiés (90 jours)

14 transactions — 0 achats et 7 ventes déclarés par les dirigeants de Edwards Lifesciences Corporation.

🏦 Hedge Funds

19 fonds institutionnels déclarent une position sur EW dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur EW.

• Edwards Lifesciences to Host Investor Event in Conjunction With TCT
• Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.